Hicks J K, Bishop J R, Sangkuhl K, Müller D J, Ji Y, Leckband S G, Leeder J S, Graham R L, Chiulli D L, LLerena A, Skaar T C, Scott S A, Stingl J C, Klein T E, Caudle K E, Gaedigk A
Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA; Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA; and Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
University of Minnesota College of Pharmacy, Department of Experimental and Clinical Pharmacology, Minneapolis, Minnesota, USA.
Clin Pharmacol Ther. 2015 Aug;98(2):127-34. doi: 10.1002/cpt.147. Epub 2015 Jun 29.
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).
选择性5-羟色胺再摄取抑制剂（SSRIs）是治疗重度抑郁和焦虑症的主要药物。细胞色素P450 2D6（CYP2D6）和细胞色素P450 2C19（CYP2C19）基因多态性会影响SSRIs的代谢，进而影响药物疗效和安全性。我们总结了已发表文献中支持这些关联的证据，并根据CYP2D6和/或CYP2C19基因型给出了氟伏沙明、帕罗西汀、西酞普兰、艾司西酞普兰和舍曲林的给药建议（最新信息见www.pharmgkb.org）。
